Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORB | Q92753 | 5/20 | 0.47 |
| ▸ | RORC | P51449 | 1/20 | 0.46 |
| ▸ | GPR52 | Q9Y2T5 | 2/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.42 |
| ▸ | SCD | O00767 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | APLNR | P35414 | 1/20 | 0.40 |
| ▸ | NCS1 | P62166 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13824043 | 0.86 | IDO1 (0.42) | LMNAALOX5NPC1MEN1KMT2A | |
| SCHEMBL13823944 | 0.81 | MAOB (0.42) | RORBRORCRXFP1LMNATSHR | |
| SCHEMBL13824041 | 0.80 | STS (0.41) | NPC1APLNRMEN1KMT2A | |
| SCHEMBL13731334 | 0.77 | HTR2C (0.47) | — | |
| SCHEMBL13728657 | 0.76 | ADORA2A (0.40) | GPR52SCDNPC1MEN1KMT2A | |
| SCHEMBL13728150 | 0.75 | KMT2A (0.43) | GPR52NPC1MEN1KMT2A | |
| SCHEMBL11504586 | 0.73 | RORB (0.60) | RORBRORCRXFP1LMNATSHR | |
| SCHEMBL15592673 | 0.73 | EGLN1 (0.41) | TSHRNPC1MEN1KMT2A | |
| SCHEMBL24611387 | 0.67 | PDE2A (0.43) | GPR52SCDMEN1KMT2A | |
| SCHEMBL29790329 | 0.67 | PDE2A (0.43) | GPR52SCDMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9328075-B2 | Pyrimidinone compounds and methods for treating influenza | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2016-05-03 | — | — | US | disclosed |
| US-9328075-B2 | Pyrimidinone compounds and methods for treating influenza | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2016-05-03 | — | — | US | disclosed |
| US-9328075-B2 | Pyrimidinone compounds and methods for treating influenza | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2016-05-03 | — | — | US | disclosed |
| US-20140079666-A1 | PYRIMIDINONE COMPOUNDS AND METHODS FOR PREVENTING AND TREATING INFLUENZA | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2014-03-20 | — | — | US | disclosed |
| US-20140079666-A1 | PYRIMIDINONE COMPOUNDS AND METHODS FOR PREVENTING AND TREATING INFLUENZA | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2014-03-20 | — | — | US | disclosed |
| US-20140079666-A1 | PYRIMIDINONE COMPOUNDS AND METHODS FOR PREVENTING AND TREATING INFLUENZA | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2014-03-20 | — | — | US | disclosed |
| WO-2012151567-A1 | PYRIMIDINONE COMPOUNDS AND METHODS FOR PREVENTING AND TREATING INFLUENZA | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2012-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140079666-A1 | PYRIMIDINONE COMPOUNDS AND METHODS FOR PREVENTING AND TREATING INFLUENZA | ADA, TYMP, ITPA | RORB 1260/4885RORC 949/4885GPR52 2841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.